WaveMan
WaveMan · Company
CAMP · Camp4 Therapeutics Corp
> Search tickers & screens ⌘K
LIVE
← All companies

CAMP Camp4 Therapeutics (CAMP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001736730
Quote by TradingView
Cluster · 4 insidersC-suite buying · 3Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
40
13F, latest reported quarter

What the filings say about CAMP

Insiders, 180 days
-$2.4M net sold
4 buyers · 2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$8.3K
1 notice

Camp4 Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Camp4 Therapeutics Corp insiders sold a net $2.4M of stock across 70 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gold Kelly
Chief Financial Officer
BUY
2026-09-02 SECtraded 2026-08-31
10,000
$39.6K
-18.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 3, 2026.
  • The trade is 100.0% of the 10,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gold Kelly bought about $39.6K of CAMP on Aug 31, 2026; 3 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-08-31 SECtraded 2026-08-27
400,000
$1.6M
-3.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Aug 24, 2026.
  • The trade is 19.7% of the 2,033,270 shares held after it.
  • 1 other insider sold within 30 days.
  • 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $1.6M of CAMP on Aug 27, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 40 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-08-26 SECtraded 2026-08-24
10
$45
-11.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Aug 21, 2026.
  • The trade is 0.0% of the 2,433,270 shares held after it.
  • 1 other insider sold within 30 days.
  • 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $45 of CAMP on Aug 24, 2026; 1 other insider sold within 30 days and 40 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-08-21 SEC
32,018
$144.1K
-15.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Aug 20, 2026.
  • The trade is 1.3% of the 2,433,280 shares held after it.
  • 1 other insider sold within 30 days.
  • 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $144.1K of CAMP on Aug 21, 2026; 1 other insider sold within 30 days and 40 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-08-21 SECtraded 2026-08-20
114,700
$520.7K
-15.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 19, 2026.
  • The trade is 4.7% of the 2,465,298 shares held after it.
  • 1 other insider sold within 30 days.
  • 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $520.7K of CAMP on Aug 20, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 40 funds added in the latest 13F quarter.
70 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 65 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.4M over 180 days
-$2.4M over 90 days
below 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
40 funds bought in last quarter
below 57% of Pharma & Biotech
Revenue
+436.5% year over year
more than 93% of Pharma & Biotech
Margin
-2298.5% net margin
below 92% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.4% of the float short (float per yahoo 2026-10-26) · 5.1 days to cover · settled 2026-09-30
below 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CAMP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.9%12M
-17%+24%+64%+105%2025-102025-122026-022026-042026-062026-082026-10 2026-08-27 · Schwab Andrew J. sold $1.6M2026-08-20 · Schwab Andrew J. sold $520.7K2026-08-19 · Schwab Andrew J. sold $214.9K2026-08-21 · Schwab Andrew J. sold $144.1K2026-08-31 · Gold Kelly bought $39.6K2026-08-03 · Young Richard A bought $27.0K2026-08-03 · Mandel-Brehm Josh bought $10.8K2026-08-03 · Gold Kelly bought $10.8K2026-08-03 · Maricich Yuri bought $10.8K2026-08-19 · Tardiff Daniel sold $8.3K2026-08-24 · Schwab Andrew J. sold $452026-08-19 · Daniel Tardiff filed to sell $8.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CAMP: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
6,307,636 sh
$27.6M
5AM Venture Management, LLC
5,869,091 sh
$25.6M
FMR LLC
4,904,339 sh
$21.4M
Vivo Capital, LLC
4,246,568 sh
$18.6M
Stonepine Capital Management, LLC
2,779,244 sh
$12.1M

Congress trades in CAMP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CAMP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Daniel Tardiff
Filed 2026-08-19
$8.3K

CAMP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Biotechnology Portfolio
$5.8M position · as of 2026-05-31
0.1%
Victory RS Science & Technology Fund
$257.5K position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$109.2K position · as of 2026-06-30
0.1%
Victory Science & Technology Fund
$781.8K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$453.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$29.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $2.4M sold by insiders over 180 days, 40 funds added last quarter, $8.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CAMP financials

Revenue growth
+436.5%
XBRL, annual
Net margin
-2298.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-2,544%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$28.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-545.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-148.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-89.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-12.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$3.5M$652.0K$350.0K
Operating income-$52.6M-$53.1M-$51.9M
Net income-$80.4M-$51.8M-$49.3M
EPS (diluted)-2.65-11.04-124.80
Operating cash flow-$29.6M-$45.6M-$44.2M
Cash$109.5M$64.0M$38.4M
SEC XBRL, fiscal years, as known on 2026-10-28

CAMP Stock Sonar score 5/7 axes

Find similar shapesCompare

CAMP ranks highest on growth (93rd percentile) and risk and compliance (66th), and lowest on profitability (17th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
17
Inputs
  • Return on equity-545.9% · 7 pct, sector of 545
  • Return on assets-148.2% · 15 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-89.5% · 29 pct, sector of 576
Growth
93
Inputs
  • Revenue growth, YoY+436.5% · 93 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
60
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.4M · 27 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
43
Inputs
  • Funds adding, latest quarter40 · 43 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
66
Inputs
  • Short interest, % of float+3.4% · 66 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.8% · 65 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CAMP filings, in plain words

Are Camp4 Therapeutics insiders buying or selling CAMP?

In the 180 days to 2026-10-28, Camp4 Therapeutics insiders were net sellers, a net $2.4M: $99.1K of purchases and $2.5M of sales reported on Form 4, by 4 buyers and 2 sellers.

Are there planned insider sales of CAMP?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $8.3K of stock; the latest, by Daniel Tardiff, was filed 2026-08-19.

Read the full summary

In the 180 days to 2026-10-28, Camp4 Therapeutics insiders were net sellers of CAMP, a net $2.4M across purchases and sales reported on Form 4 by 4 buyers and 2 sellers. Sales outweighed purchases more than tenfold by value. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $8.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies